NCT00215371已完成2 期
Study in Patients With Asthma
Dey3 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2002年7月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 32
- 试验地点
- 3
- 主要终点
- Primary: The primary efficacy outcome is measure of lung function.
研究概览
简要总结
The purpose of this study is to determine which dose of the investigational drug is safest and most effective compared to the control group.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 5 Years 至 11 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Require the regular use of an inhaled beta-2-selective adrenergic agent.
- •No clinically significant abnormalities on the medical history, physical examination, and clinical laboratory tests.
排除标准
- •Active acute or chronic disorders of the respiratory system within one month prior to screening.
- •Smoking history within the past 12 months or greater than a lifetime 10 pack-year smoking history.
- •Debilitating systemic and/or life-threatening diseases.
结局指标
主要结局
Primary: The primary efficacy outcome is measure of lung function.
次要结局
- Secondary: Change in lung function will be examined as a secondary efficacy outcome, as well as vital signs, physical examination, adverse event reporting,etc.
研究者
研究点 (3)
Loading locations...
相似试验
已完成
2 期
Study in Patients With AsthmaAsthmaNCT00215358Dey32
已完成
2 期
Study in Patients With AsthmaAsthmaNCT00215397Dey16
已完成
2 期
Study in Patients With AsthmaAsthmaNCT00215410Dey36
已完成
3 期
New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe AsthmaAsthmaNCT00393952SkyePharma AG557
已完成
3 期
Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With AsthmaAsthmaNCT00393991SkyePharma AG475